Dear Prospective Industry Partner,
This is a very exciting time to be involved in cancer research! Following the disruption by the pandemic, we are resuming our biennial Cancer Metastasis Congress as the 9th International Cancer Metastasis Congress to be held on May 4th-6th, 2023 in San Francisco. Since the inauguration of our biannual meeting on cancer metastasis in 2005,
we have summarized these meetings in our textbook on Cancer Metastasis through the Lymphovascular System (https://link.springer.com/book/10.1007/978-3-030-93084-4). We had a very successful meeting in 2019, which culminated in the publication of a Special Issue, entitled, Novel Frontiers in Cancer Metastasis
(https://link.springer.com/journal/10585/volumes-and-issues/39-1utm_source=toc&utm_medium=email&utm_campaign=toc_10585_39_1&utm_content=etoc_springer_20220330). We will devote our 2023 Cancer Metastasis Congress to the Molecular Mechanisms of Cancer Metastasis. A panel of distinguished experts in cancer metastasis has been chosen to serve in the organizing committee. The 2023 Cancer Metastasis Congress will bring together many renowned international experts in clinical oncology, immunobiology, pharmacology, molecular biology, and molecular imaging to discuss the molecular mechanisms of cancer metastasis and their clinical implications as we enter the era of precision medicine. This meeting with the invited presentations will form the basis of a set of review articles to be published online in Clinical and Experimental Metastasis and in print in a Special Issue: Molecular Mechanisms of Cancer Metastasis.
With advancements in cancer care and patient-centered treatment planning, cancer survivors today live longer and enjoy a vastly improved quality of life than previously thought imaginable. We hope you will participate in 9th International Congress on Cancer Metastasis, scheduled for May 4th-6th 2023 in San Francisco, California at the JW Marriott.
The Symposium is sponsored by the Sentinel Node Oncology Foundation, (https://www.snofoundation.com), a 501(c)(3) non-profit organization founded in 2003 to advance the care and treatment of patients with solid cancer and to help develop new preventative strategies, diagnostics, and treatments. We will also have additional sponsors for this much anticipated meeting.
The Organizing Committee is building a program that follows the process of cancer metastasis from origins at the molecular level to genomic identification to precision treatment and survival. The theme of the Symposium is to track the single cell in our body, that has become a mutant cell, which proliferates with resultant mutants being selected to become the fittest clone to spread through the lymphovascular system using the sentinel lymph node as the major gateway to distant sites to cause devastation to the body. It is a journey that we must understand from a molecular
level so that it can be stopped before the mutants go awry.
It is the goal of this biennial symposium to bring together basic scientists, oncologists, surgeons, and radiologists from around the world, resulting in a cross-fertilization of ideas that will enhance the translation of basic science into clinical application—and challenge basic scientists with clinical issues.
Target Audience: Based on the attendance history we anticipate 175 – 225 participants, a collegial atmosphere with ample opportunity to network and meet with every attendee with a potential interest in your product or services. These attendees will be primarily physicians (75%) specializing in surgery, oncology, molecular imaging, plastic surgery, radiation oncology, hematology, thoracic medicine with the remainder a mixture of predominately PhD/scientists from both academia and biotechnology as well as a smaller groups of attendees who are in training, regulatory or from industry.
In addition to plenary sessions with distinguished guest faculty, time will be allotted for integrated oral abstract presentations and poster sessions peer-selected from submitted abstracts by attendees, young investigators, and trainees.
A separate ballroom has been reserved for the poster sessions together with commercial exhibits and industry sponsored breakfast and lunch symposia on the most significant oncology topics related to late breaking results from clinical trials in cancer therapy.
We are confident that this 3 day CME accredited activity in San Francisco will make a significant impact by updating the oncologists with the latest development in cancer therapy and bringing the clinical relevance of cancer metastasis to the basic scientists.
Thank you for your consideration and we look forward to seeing you in San Francisco!
Co-Chairs for the 2023 9th International Cancer Metastasis Congress
Stanley P. L. Leong, MD, Co-Chair
President, Sentinel Node Oncology FoundationChief of Cutaneous Oncology
Associate Director of the Melanoma Program
Center for Melanoma Research and Treatment
California Pacific Medical Center
Senior Scientist
California Pacific Medical Center Research Institute, San Francisco, USA
S D Nathanson, MD, FACS, FSSO, Symposium Co-Chair
Breast Surgical Oncology, Henry Ford Health System
Jonathan S. Zager, MD, Co-Chair
Treasurer, Sentinel Node Oncology Foundation
Professor of Surgery, Cutaneous Oncology and Sarcoma Departments
Chair of Graduate Medical Education
Moffitt Cancer Center, Tampa, USA
Share this: